Tharimmune, Inc. Common Stock (THAR)
Tharimmune, Inc. (THAR) is a biotechnology company focused on developing innovative diagnostic and therapeutic solutions for immune-related diseases. Utilizing advanced immunoassay technologies, Tharimmune aims to improve disease detection, monitor immune responses, and develop targeted treatments, primarily serving the healthcare and biotech sectors.
Company News
Five Nasdaq-listed stocks significantly outperformed the index in August, with gains ranging from 188% to 378%, driven by factors like drug development progress, FDA approvals, and strategic partnerships.
U.S. stock futures were slightly lower as the Jackson Hole Economic Symposium begins, with focus on Federal Reserve Chair Jerome Powell's upcoming speech and key corporate earnings reports from Walmart, Intuit, and Ross Stores.
Tharimmune (THAR) announces positive data from a phase I study on TH104 and the development timeline in chronic pruritis in primary biliary cholangitis indication.